Loading...
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
INTRODUCTION: The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival. However, the drug has little effect on the underlying bone marrow fibrosis o...
Na minha lista:
| Udgivet i: | Expert Opin Orphan Drugs |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577425/ https://ncbi.nlm.nih.gov/pubmed/33094033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21678707.2019.1664900 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|